Home / Endoglin/CD105 / Human Endoglin/CD105 Quantikine ELISA Kit

Human Endoglin/CD105 ELISA Kit - Quantikine

Catalog #: DNDG00
41 Citations 1 Review Datasheet / COA / SDS
Catalog # Availability Size / Price Qty
DNDG00
Control Products Available
QC23: Quantikine Immunoassay Control Group 8
Human Endoglin/CD105 ELISA Standard Curve
2 Images
Product Details
Procedure
Citations (41)
FAQs
Supplemental Products
Reviews (1)
Summary Precision Recovery Linearity Data Examples Product Datasheets Preparation and Storage Background Related Research Areas

Human Endoglin/CD105 Quantikine ELISA Kit Summary

Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Assay Length
4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL)
Sensitivity
0.03 ng/mL
Assay Range
0.2 - 10 ng/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma)
Specificity
Natural and recombinant human Endoglin
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
Interference
No significant interference observed with available related molecules.

Product Summary

The Quantikine Human Endoglin Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human Endoglin in cell culture supernates, serum, and plasma. It contains NS0-expressed recombinant human Endoglin and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human Endoglin showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring Endoglin.

Precision

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in forty separate assays to assess inter-assay precision

Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean (ng/mL) 0.617 1.67 3.14 0.659 1.8 3.47
Standard Deviation 0.017 0.053 0.094 0.044 0.117 0.22
CV% 2.8 3.2 3 6.7 6.5 6.3

Recovery

The recovery of Endoglin spiked to levels throughout the range of the assay was evaluated in cell culture media.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 101 92-111

Linearity

To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Endoglin were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human Endoglin/CD105 ELISA Linearity

Scientific Data

N/A Human Endoglin/CD105 ELISA Standard Curve View Larger

Human Endoglin/CD105 ELISA Standard Curve

Product Datasheets

You must select a language.

x
Product Datasheet
COA
SDS

Preparation and Storage

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: Endoglin/CD105

Endoglin (CD105) is a transmembrane type III receptor for TGF-beta superfamily ligands and plays an important role in smooth muscle differentiation, angiogenesis, and neovascularization. It is highly expressed on proliferating vascular endothelial cells, chondrocytes, and syncytiotrophoblasts of term placenta. Human Endoglin haploinsufficiency can a cause the vascular disorder, hereditary hemorrhagic telangiectasia type I. Elevated levels of anti-angiogenic soluble Endoglin contribute to pathogenicity in preeclampsia. Endoglin associates with the receptors TGF-beta RII, Activin RIIA or RIIB, BMPR-IA/ALK-3, or BMPR-IB/ALK6 and enhance binding of Activin A, BMP-2, -7, -9, TGF-beta 1, or TGF-beta 3. Endoglin can either enhance or inhibit signaling through these receptor complexes.

Entrez Gene IDs:
2022 (Human); 13805 (Mouse); 497010 (Rat)
Alternate Names:
CD105 antigen; CD105; Endoglin; ENDOsler-Rendu-Weber syndrome 1; ENG; HHT1FLJ41744; ORW; ORW1
&#9888; WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Assay Procedure

Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
    3. 100 µL Assay Diluent
  3.   Add 100 µL of Assay Diluent to each well.
    4. 50 µL Standard, Control, or Sample
  4.   Add 50 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours on a horizontal orbital microplate shaker.
  5.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.
    6. 200 µL Conjugate
  6.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours on the shaker.
  7.   Aspirate and wash 4 times.
    8. 200 µL Substrate Solution
  8.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes on the benchtop. PROTECT FROM LIGHT.
    9. 50 µL Stop Solution
  9.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

Citations for Human Endoglin/CD105 Quantikine ELISA Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

41 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. A Novel Dual-Function Redox Modulator Relieves Oxidative Stress and Anti-Angiogenic Response in Placental Villus Explant Exposed to Hypoxia-Relevance for Preeclampsia Therapy
    Authors: Pintye, D;Sziva, RE;Mastyugin, M;Young, BC;Jacas, S;Török, M;Salahuddin, S;Jagtap, P;Southan, GJ;Zsengellér, ZK;
    Biology
    Species: Human
    Sample Types: Cell Culture Supernates
  2. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles loaded with TFCP2 activate Wnt/?-catenin signaling to alleviate preeclampsia
    Authors: Yang, Z;Jia, X;Deng, Q;Luo, M;Hou, Y;Yue, J;Mei, J;Shan, N;Wu, Z;
    International immunopharmacology
    Species: Human
    Sample Types: Serum
  3. Vasoactive Soluble Endoglin: A Novel Biomarker Indicative of Reperfusion after Cerebral Large-Vessel Occlusion
    Authors: A Haarmann, C Vollmuth, AM Kollikowsk, PU Heuschmann, M Pham, G Stoll, H Neugebauer, MK Schuhmann
    Cells, 2023-01-11;12(2):.
    Species: Human
    Sample Types: Plasma
  4. Obstructive Sleep Apnea Is Associated With Late-Onset Preeclampsia in Overweight Pregnant Women in Korea
    Authors: G Ryu, YM Kim, KE Lee, SJ Choi, SD Hong, YG Jung, SY Oh, HY Kim
    Journal of Korean Medical Science, 2023-01-09;38(2):e8.
    Species: Human
    Sample Types: Serum
  5. Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction
    Authors: W Dymara-Kon, M Laskowska, E Grywalska, A Hymos, A B?a?ewicz, B Leszczy?sk
    International Journal of Molecular Sciences, 2023-01-04;24(2):.
    Species: Human
    Sample Types: Serum
  6. The Relationship between Angiogenic Factors and Energy Metabolism in Preeclampsia
    Authors: A Abascal-Sa, M Duque-Alco, V Fioravantt, E Antolín, E Fuente-Lue, M Haro, MP Ramos-Álva, G Perdomo, JL Bartha
    Nutrients, 2022-05-23;14(10):.
    Species: Human
    Sample Types: Serum
  7. Placental lesions and differential expression of pro-and anti-angiogenic growth mediators and oxidative DNA damage marker in placentae of Ghanaian suboptimal and optimal health status pregnant women who later developed preeclampsia
    Authors: EO Anto, DA Coall, EA Asiamah, OO Afriyie, O Addai-Mens, YA Wiafe, W Owiredu, C Obirikoran, ME Annani-Ako, NA Titiloye, E Adua, E Acheampong, EA Adu, S Opoku, AO Anto, A Tawiah, Y Wang, W Wang
    PLoS ONE, 2022-03-21;17(3):e0265717.
    Species: Human
    Sample Types: Plasma
  8. High Soluble Endoglin Levels Affect Aortic Vascular Function during Mice Aging
    Authors: I Nejmanová, B Vitverová, S Eissazadeh, K Tripská, IC Igreja Sa, R Hyšpler, I N?me?kova, M Pericacho, P Nachtigal
    Journal of cardiovascular development and disease, 2021-12-04;8(12):.
    Species: Human
    Sample Types: Whole Blood
  9. Generation of a Soluble Form of Human Endoglin Fused to Green Fluorescent Protein
    Authors: L Ruiz-Llore, MC Vega, FJ Fernández, C Langa, NW Morrell, PD Upton, C Bernabeu
    International Journal of Molecular Sciences, 2021-10-19;22(20):.
    Species: Human
    Sample Types: Cell Culture Supernates
  10. Pregnancy-Induced High Plasma Levels of Soluble Endoglin in Mice Lead to Preeclampsia Symptoms and Placental Abnormalities
    Authors: L Pérez-Roqu, E Núñez-Góme, A Rodríguez-, C Bernabéu, JM López-Novo, M Pericacho
    International Journal of Molecular Sciences, 2020-12-26;22(1):.
    Species: Human
    Sample Types: Plasma
  11. Circulating miRNAs Associated with Dysregulated Vascular and Trophoblast Function as Target-Based Diagnostic Biomarkers for Preeclampsia
    Authors: S Kim, M Park, JY Kim, T Kim, JY Hwang, KS Ha, MH Won, S Ryoo, YG Kwon, YM Kim
    Cells, 2020-08-31;9(9):.
    Species: Human
    Sample Types: Serum
  12. Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma
    Authors: SP Polster, A Sharma, C Tanes, AT Tang, P Mericko, Y Cao, J Carrión-Pe, R Girard, J Koskimäki, D Zhang, A Stadnik, SG Romanos, SB Lyne, R Shenkar, K Yan, C Lee, A Akers, L Morrison, M Robinson, A Zafar, K Bittinger, H Kim, JA Gilbert, ML Kahn, L Shen, IA Awad
    Nat Commun, 2020-05-27;11(1):2659.
    Species: Human
    Sample Types: Plasma
  13. Sleep-disordered breathing does not impact maternal outcomes in women with hypertensive disorders of pregnancy
    Authors: DL Wilson, ME Howard, AM Fung, FJ O'Donoghue, M Barnes, M Lappas, SP Walker
    PLoS ONE, 2020-04-27;15(4):e0232287.
    Species: Human
    Sample Types: Serum
  14. Potential Role of Circulating Endoglin in Hypertension via the Upregulated Expression of BMP4
    Authors: E Gallardo-V, L Gamella-Po, L Perez-Roqu, JL Bartha, I Garcia-Pal, JI Casal, JM López-Novo, M Pericacho, C Bernabeu
    Cells, 2020-04-16;9(4):.
    Species: Human
    Sample Types: Cell Culture Supernates
  15. Hydroxychloroquine Mitigates the Production of 8-Isoprostane and Improves Vascular Dysfunction: Implications for Treating Preeclampsia
    Authors: RA Rahman, P Murthi, H Singh, S Gurungsing, B Leaw, JC Mockler, R Lim, EM Wallace
    Int J Mol Sci, 2020-04-03;21(7):.
    Species: Human
    Sample Types: Placenta
  16. MMP-12, Secreted by Pro-Inflammatory Macrophages, Targets Endoglin in Human Macrophages and Endothelial Cells
    Authors: M Aristorena, E Gallardo-V, M Vicen, M de Las Cas, L Ojeda-Fern, C Nieto, FJ Blanco, AC Valbuena-D, LM Botella, P Nachtigal, AL Corbi, M Colmenares, C Bernabeu
    Int J Mol Sci, 2019-06-25;20(12):.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: Western Blot
  17. Sulphadoxine-pyrimethamine plus azithromycin may improve birth outcomes through impacts on inflammation and placental angiogenesis independent of malarial infection
    Authors: HW Unger, AP Hansa, C Buffet, W Hasang, A Teo, L Randall, M Ome-Kaius, S Karl, AA Anuan, JG Beeson, I Mueller, SJ Stock, SJ Rogerson
    Sci Rep, 2019-02-19;9(1):2260.
    Species: Human
    Sample Types: Plasma
  18. LIFR increases the release of sEng via the up-regulation of MMP14 expression in PE
    Authors: H Li, J Yao, X Chang, J Wu, T Duan, K Wang
    Reproduction, 2018-01-23;0(0):.
    Species: Human
    Sample Types: Plasma
  19. Circulating soluble endoglin modifies the inflammatory response in mice
    Authors: L Ruiz-Remol, C Ollauri-Ib, L Pérez-Roqu, E Núñez-Góme, F Pérez-Barr, JM López-Novo, M Pericacho, A Rodríguez-
    PLoS ONE, 2017-11-16;12(11):e0188204.
    Species: Mouse
    Sample Types: Plasma
  20. Endothelial Dysfunction in Severe Preeclampsia is Mediated by Soluble Factors, Rather than Extracellular Vesicles
    Authors: M O'Brien, D Baczyk, JC Kingdom
    Sci Rep, 2017-07-19;7(1):5887.
    Species: Human
    Sample Types: Tissue Culture Supernates
  21. Lipoprotein apheresis in the treatment of dyslipidaemia - the Czech Republic experience
    Authors: V Bláha, M Bláha, M Lánská, D Solichová, L Kujovská K, E Havel, P Vyroubal, Z Zadák, P Žák, L Sobotka
    Physiol Res, 2017-04-05;66(0):S91-S100.
    Species: Human
    Sample Types: Serum
  22. Plasma Soluble Endoglin Levels Are Inversely Associated With the Severity of Coronary Atherosclerosis
    Authors: Yukihiko Momiyama
    Arterioscler. Thromb. Vasc. Biol., 2016-10-27;0(0):.
    Species: Human
    Sample Types: Plasma
  23. Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia
    Authors: Ingrid C Weel
    PLoS ONE, 2016-06-17;11(6):e0157584.
    Species: Human
    Sample Types: Tissue Homogenates
  24. High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta.
    Authors: Nemeckova I, Serwadczak A, Oujo B, Jezkova K, Rathouska J, Fikrova P, Varejckova M, Bernabeu C, Lopez-Novoa J, Chlopicki S, Nachtigal P
    PLoS ONE, 2015-03-13;10(3):e0119665.
    Species: Mouse
    Sample Types: Plasma
  25. Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury.
    Authors: White W, Garrett A, Craici I, Wagner S, Fitz-Gibbon P, Butters K, Brost B, Rose C, Grande J, Garovic V
    PLoS ONE, 2014-03-24;9(3):e92693.
    Species: Human
    Sample Types: Serum
  26. Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia.
    Authors: Rana S, Cerdeira A, Wenger J, Salahuddin S, Lim K, Ralston S, Thadhani R, Karumanchi S
    PLoS ONE, 2012-10-26;7(10):e48259.
    Species: Human
    Sample Types: Plasma
  27. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
    Authors: Widemann B, Kim A, Fox E, Baruchel S, Adamson P, Ingle A, Glade Bender J, Burke M, Weigel B, Stempak D, Balis F, Blaney S
    Clin Cancer Res, 2012-09-07;18(21):6011-22.
    Species: Human
    Sample Types: Plasma
  28. MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin.
    Authors: Kaitu'u-Lino TJ, Palmer K, Tuohey L, Ye L, Tong S
    PLoS ONE, 2012-06-29;7(6):e39864.
    Species: Human
    Sample Types: Cell Culture Supernates
  29. Circulating soluble endoglin levels in pregnant women in Cameroon and Malawi--associations with placental malaria and fetal growth restriction.
    Authors: Silver KL, Conroy AL, Leke RG, Leke RJ, Gwanmesia P, Molyneux ME, Wallace DT, Rogerson SJ, Kain KC
    PLoS ONE, 2011-09-22;6(9):e24985.
    Species: Human
    Sample Types: Plasma
  30. Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer.
    Authors: Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Stoblen F, Lichtenegger W, Sehouli J, Kummel S
    Anticancer Res., 2011-08-01;31(8):2651-5.
    Species: Human
    Sample Types: Serum
  31. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
    Authors: Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM
    Clin. Cancer Res., 2011-06-20;17(15):5113-22.
    Species: Human
    Sample Types: Plasma
  32. Effect of smoking on circulating angiogenic factors in high risk pregnancies.
    Authors: Jeyabalan A, Powers RW, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M, Caritis S, Roberts JM, Kuller J, Cotroneo M, Kamon T, Mercer B, Ramsey R, Paul R, Rabello Y, McCart D, Mueller E, Goldenberg R, Copper R, Sorokin Y, Norman G, Millinder A, Christmas JT, McCoy S, Elder S, Elder N, Carter B, Pemberton V, Thurnau G, Meier A, Minton V, Meis P, Swain M, Moawad AH, Jones P, Iams JD, Meadows S, Brenner S, Collins B, Newman RB, Carter SG, Romero R, Sabo V, Thom E, Bain RP, MacPherson C, Johnson D, Fischer ML, McNellis D, Spong C, Catz C, Yaffe S
    PLoS ONE, 2010-10-12;5(10):e13270.
    Species: Human
    Sample Types: Serum
  33. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Authors: Powers RW, Jeyabalan A, Clifton RG
    PLoS ONE, 2010-10-11;5(10):e13263.
    Species: Human
    Sample Types: Serum
  34. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia.
    Authors: Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, Fazekas de St Groth B, Nanan R
    J. Immunol., 2009-11-13;183(11):7023-30.
    Species: Human
    Sample Types: Serum
  35. A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia.
    Authors: Blankley RT, Gaskell SJ, Whetton AD
    BJOG, 2009-08-04;116(11):1473-80.
    Species: Human
    Sample Types: Plasma
  36. Soluble endoglin modulates aberrant cerebral vascular remodeling.
    Authors: Chen Y, Hao Q, Kim H, Su H, Letarte M, Karumanchi SA, Lawton MT, Barbaro NM, Yang GY, Young WL
    Ann. Neurol., 2009-07-01;66(1):19-27.
    Species: Human
    Sample Types: Tissue Homogenates
  37. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
    Authors: Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI
    Clin. Cancer Res., 2008-06-15;14(12):3785-91.
    Species: Human
    Sample Types: Plasma
  38. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy.
    Authors: Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF
    Clin. Cancer Res., 2008-06-01;14(11):3362-6.
    Species: Human
    Sample Types: Plasma
  39. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer.
    Authors: Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, Shariat SF
    Clin. Cancer Res., 2008-03-01;14(5):1418-22.
    Species: Human
    Sample Types: Plasma
  40. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Authors: Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA
    N. Engl. J. Med., 2006-09-07;355(10):992-1005.
    Species: Human
    Sample Types: Serum
  41. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer.
    Authors: Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, Boneberg EM
    Br. J. Cancer, 2006-02-27;94(4):524-31.
    Species: Human
    Sample Types: Serum

FAQs

  1. Does this ELISA detect the L or S isoform of Endoglin?

    • Both isoforms are expected to be measured in this Endoglin ELISA. This assay recognizes the soluble, extracellular portion of the protein which is identical for the L & S isoforms. The differences between L & S Endoglin are located within the cytoplasmic region of the protein.

  2. Does this ELISA detect monomeric or dimeric Endoglin?

    • This assay is confirmed to measure dimeric soluble Endoglin. This assay has not been evaluated for reactivity with monomeric Endoglin.

View all ELISA FAQs
Loading...

Reviews for Human Endoglin/CD105 Quantikine ELISA Kit

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human Endoglin/CD105 Quantikine ELISA Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human Endoglin/CD105 Quantikine ELISA Kit
By Anonymous on 11/08/2022
Sample Tested: Plasma,Urine

Normal, healthy plasma was in range at 10-fold dilution and showed good linearity. Concentrations in normal, healthy urine were below the standard curve at 10-fold dilution so would recommend using a lower dilution factor.

Human Endoglin/CD105 Quantikine ELISA Kit DNDG00